Skip to main content

Table 2 Characteristics matching in Risperidone ISM versus Paliperidone palmitate comparison, for the tolerability base case analysis

From: Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Study

PRISMA-3 OLE (Full population)

Gopal 2010 [28]

Intervention

Risperidone ISM

PP

Characteristic

Pre-matching (N = 215)

Post-matching (ESS = 42)

(N = 388)

Age [Mean (SD)]

39.1 (10.9)

37.3 (10.8)

37.3 (10.8)

Baseline PANSS total score [Mean (SD)]

71.3 (14.8)

58.2 (18.2)

58.2 (18.2)

Baseline CGI-S score [Median]

3.0

3.0

3.0

Race: white [%]

84.7

69.0

69.0

  1. CGI-S clinical global impressions—severity scale, ESS effective sample size, MAIC matching-adjusted indirect comparison, OLE open-label extension, PANSS positive and negative syndrome scale, PP paliperidone palmitate, SD standard deviation